NCT00206284

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

A 4-week, Randomised, Double-blind, Multicentre, Dose-finding Phase IIb Study With AZD0865 25, 50, 75 mg and Esomeprazole 20 mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,400 (planned)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate the safety and tolerability of AZD0865.

Conditions

• GERD Without Erosive Esophagitis

Interventions

Type	Name	Description
DRUG	AZD0865

Timeline

• Start date: 2004-05-01
• Completion: 2005-04-01
• First posted: 2005-09-21
• Last updated: 2013-01-04

Locations

202 sites across 10 countries: United States, Canada, Denmark, Finland, France, Germany, Italy, Norway, Sweden, United Kingdom